
The primary research purpose is to compare the long‐term cost‐effectiveness of semaglutide (SEMA) with dulaglutide (DULA) for patients with inadequately controlled type 2 diabetes throughout their lifetime. In addition, this study also aimed to investigate a further price cut for SEMA to provide sound advice for government drug price adjustments. The study's findings suggested that SEMA is expected to be a cost‐effective choice compared with DULA for patients with type 2 diabetes inadequately controlled from the cost‐utility analysis. However, there is still scope to further reduce the annual cost of SEMA.
Like
Save
Share